Xiaobo Wang, PhD profile page

Xiaobo Wang is vice president and general manager for cell function and phenotyping business at Agilent. Dr. Wang is a world-renowned expert and leader in the life science tool space for cell sensors, cell processing and cell assay technologies. Since joining Agilent in 2018 through the acquisition of ACEA Biosciences, Wang has been leading the development and commercialization of innovative real-time cell analysis platforms and next-generation flow cytometry systems. By focusing on meeting customer needs in the cell and gene therapy and immune–oncology market, Wang led the Agilent Cell Function and Phenotyping team to achieve the penetration and adoption of Agilent cell analysis technologies and solutions in these emerging and fast-growing markets. Prior to joining Agilent, Wang was the co-founder and chief technology officer of ACEA Biosciences where, for over 16 years, he led the ACEA team for the invention and commercialization of electronic sensor platform for label-free, real-time cell-based assays as well as NovoCyte flow cytometry technologies. Before founding ACEA, Wang was the senior director for R&D at AVIVIA Bioscience for about three years. Prior to that, he was a faculty member at the University of Texas MD Anderson Cancer Center. Over the years, Wang has published more than 60 scientific publications and has over 50 issued US patents in various areas of cell processing, cell analysis and biosensor technologies.